Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BioNTech's Trastuzumab Pamirtecan Investigational Next-generation Antibody Drug-conjugate Targeting Her-2, Met Its Primary Endpoint Of Progression Free Survival In Interim Analysis Of A Phase 3 Trial Conducted In China

Author: Benzinga Newsdesk | September 05, 2025 05:37am

 BioNTech SE (NASDAQ:BNTX) and Duality Biologics (Suzhou) Co., Ltd. ("DualityBio") today announced that the pivotal Phase 3 trial (NCT06265428) which DualityBio is conducting in China to evaluate trastuzumab pamirtecan (BNT323/DB-1303) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and a taxane-based chemotherapy met its primary endpoint of p

Posted In: BNTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist